# Junta clínica — PT-pseudo_20ba3f0f6ca0 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_20ba3f0f6ca0",
  "pid": "PT-pseudo_20ba3f0f6ca0",
  "task": 1,
  "psa": 4.8,
  "age": 65,
  "months": 3,
  "pirads": "4",
  "psad": 0.086,
  "psav": 0.35,
  "psap": 3.8,
  "vol": 56.0,
  "dre": "Nodus",
  "bx": "None",
  "cspca": 0.7257912,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 4.8 ng/mL. PI-RADS 4. PSAD 0.09. Prostate volume 56 mL. DRE nodus. csPCa 0.73.",
  "pmhx": [],
  "allergies": [],
  "vitals": {
    "weight": "76 kg",
    "height": "188 cm",
    "bmi": "21.5",
    "bp": "131/58 mmHg",
    "hr": "71 bpm",
    "smoking": "Ex-smoker (11 pack-yr, quit 2023)",
    "last_dental": "6 mo ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "01 Jan 2025",
  "enc_ref": "Dr. C. Peters (GP)",
  "enc_type": "Follow-up - PSA + MRI",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "A recent elevation of prostate-specific antigen to 4.8 ng/mL, coupled with a multiparametric MRI conducted at Jeroen Bosch Ziekenhuis, prompted this consultation."
    },
    {
      "s": "History",
      "t": "A semi-retired musician with a smoking history of 11 pack-years (cessation in 2023) seeks evaluation for a progressively rising PSA and recent imaging results. He reports zero lower urinary tract symptoms, denies haematuria, bone pain, or unexplained weight loss, and maintains a daily 45-minute walking routine alongside a modest alcohol intake of roughly 2 units weekly. Following a recent move, he now shares a residence with his sister, who acts as his next of kin, while his marital status remains married though he currently lives apart from his spouse. Past medical encounters include a routine audiology assessment for mild hearing loss and a dermatology visit for actinic keratosis surveillance; otherwise, his health history is clear, with no comorbidities and no active medications. His prior biopsy bucket remains None. He relies on written summaries during consultations due to mild hearing impairment."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: firm, mobility: unrestricted, asymmetry: Nodus palpable in the right mid-gland peripheral zone. Abdominal and cardiovascular assessments show no abnormalities, recording a blood pressure of 131/58 mmHg and a regular heart rate of 71 bpm. Peripheral lymphadenopathy and hepatosplenomegaly are absent."
    }
  ],
  "occupation": "musician (semi-retired)",
  "marital": "Married",
  "living": "Recently relocated; lives with sister",
  "next_of_kin": "Sibling (sister)",
  "recent_other": [
    "Audiology — hearing test",
    "Dermatology — actinic keratosis check"
  ],
  "alcohol": "2 units / week",
  "exercise": "Walking 45 min/day",
  "ipss": "IPSS score: 0/35 (mild LUTS)",
  "admin": "Hard of hearing — speak clearly; prefers written summaries.",
  "mri_hospital": "Jeroen Bosch Ziekenhuis ('s-Hertogenbosch)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_20ba3f0f6ca0
Task: 1

Encounter: Urology - outpatient on 01 Jan 2025.
Referrer: Dr. C. Peters (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 65-year-old male
  - PSA: 4.8 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.086 ng/mL²
  - PSA velocity: 0.35 ng/mL/yr
  - Prior PSA: 3.8 ng/mL
  - Prostate volume: 56.0 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7257912 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 4.8 ng/mL. PI-RADS 4. PSAD 0.09. Prostate volume 56 mL. DRE nodus. csPCa 0.73.

Vitals: weight 76 kg, height 188 cm, BMI 21.5, BP 131/58 mmHg, HR 71 bpm. Smoking: Ex-smoker (11 pack-yr, quit 2023).

Chief complaint: A recent elevation of prostate-specific antigen to 4.8 ng/mL, coupled with a multiparametric MRI conducted at Jeroen Bosch Ziekenhuis, prompted this consultation.

History: A semi-retired musician with a smoking history of 11 pack-years (cessation in 2023) seeks evaluation for a progressively rising PSA and recent imaging results. He reports zero lower urinary tract symptoms, denies haematuria, bone pain, or unexplained weight loss, and maintains a daily 45-minute walking routine alongside a modest alcohol intake of roughly 2 units weekly. Following a recent move, he now shares a residence with his sister, who acts as his next of kin, while his marital status remains married though he currently lives apart from his spouse. Past medical encounters include a routine audiology assessment for mild hearing loss and a dermatology visit for actinic keratosis surveillance; otherwise, his health history is clear, with no comorbidities and no active medications. His prior biopsy bucket remains None. He relies on written summaries during consultations due to mild hearing impairment.

Physical examination: DRE — texture: firm, mobility: unrestricted, asymmetry: Nodus palpable in the right mid-gland peripheral zone. Abdominal and cardiovascular assessments show no abnormalities, recording a blood pressure of 131/58 mmHg and a regular heart rate of 71 bpm. Peripheral lymphadenopathy and hepatosplenomegaly are absent.

Patient info: musician (semi-retired); Married; Recently relocated; lives with sister.
Next of kin: Sibling (sister).

Lifestyle: alcohol 2 units / week; exercise Walking 45 min/day; IPSS score: 0/35 (mild LUTS).

Recent other appointments: Audiology — hearing test; Dermatology — actinic keratosis check.
Admin: Hard of hearing — speak clearly; prefers written summaries.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-CLASSIFIER

*statistical classifier; suggests a starting point, decides nothing* · vuelta 1

A classifier trained only to open the discussion, not to close it. Here is its bid.

SUGGESTION: BIOPSY   p(biopsy) = 0.70
  uncertainty  +/- 0.12 (95% CI 0.48-0.93); among patients it cannot tell apart the outcome was 0.88 of 1.00 mixed
  confidence   MODERATE — in this tier it was right 80% of the time over 20 labelled cases

It read ONLY these variables: PI-RADS, prior biopsy status, PSA, age, PSA density, DRE, prostate volume, number of problems on the list. Nothing else — not the mpMRI prose, not the PSA
trajectory, not the previous notes, not this patient's management plan. Values it could not
read for this patient: none.
Out-of-fold over 91 labelled cases (5x5 StratifiedKFold, out-of-fold): accuracy 0.714 against a
majority-class baseline of 0.615, AUC 0.789, F1(yes) 0.78.

The final call is the senior urologist's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: never biopsied. My criterion answers BIOPSY.

The criterion: sample when the mpMRI shows a PI-RADS 3 or higher lesion; defer at PI-RADS 1-2. In the labelled series this criterion matched the reading urologist in 24 of 24 cases in exactly this situation.

Like the classifier, I have read ONLY the visible panel — not the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory panel. Departing from me needs a specific
finding from a document somebody actually opened, named out loud. Not a restatement of the
panel numbers I already used.

## Intervención 5 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline suggests that a PI-RADS threshold of $\ge 3$ is used to trigger biopsy. It also notes that for patients with suspected organ-confined disease, combining targeted biopsy with perilesional sampling is recommended when MRI is positive (i.e., PI-RADS $\ge 4$).

WHAT THE CLASSIFIER'S BID DOES NOT SETTLE
The classifier's suggestion of biopsy is not sufficiently informed by the guideline because it fails to incorporate the specific risk stratification provided by the PI-RADS score. The guideline sets a threshold of PI-RADS $\ge 3$ to trigger biopsy, a variable the classifier could not read. Furthermore, the guideline discusses risk-adapted strategies, such as combining targeted biopsy with perilesional sampling for PI-RADS $\ge 4$ lesions, which the classifier's simple yes/no decision cannot represent.

WHAT WE STILL NEED
The mpMRI prose - the mpMRI prose states the PI-RADS score is 4, which is $\ge 3$, which aligns with the guideline's trigger. This supports the consideration of biopsy.
The PSA trend - the PSA velocity is $0.35 \text{ ng/mL/yr}$, which is a factor in risk stratification that the guideline makes decisive.
The previous notes - the notes state "Prior biopsy: None," which is a factor in the guideline, as prior biopsy status is a significant predictor.
The laboratory results - the laboratory results show a PSA density of $0.086 \text{ ng/mL/cc}$, which is a factor in the guideline, as PSA density is used in risk-based matrices.

## Intervención 6 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 1

This case hinges on whether we establish the full context from the MRI report and the PSA trend to confirm the guideline-suggested approach for a PI-RADS 4 lesion.

Before anyone argues, this is what I want established, and by whom.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> To establish the mpMRI prose regarding lesion characteristics.
  psa_trend (get_psa_trend) -> To establish the PSA velocity and risk stratification.
  previous_notes (get_previous_notes) -> To confirm the prior biopsy status and management context.

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. What does the mpMRI prose state regarding the lesion size and extraprostatic extension?
  Q2. What does the PSA trend reveal about the risk stratification?

## Intervención 7 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The mpMRI prose states the PI-RADS 4 lesion is in the right peripheral zone mid-gland, spanning approximately 12 x 9 x 8 mm, and shows early, focal enhancement.
psa_trend
The PSA trend reveals a PSA velocity of $0.35 \text{ ng/mL/yr}$ between the measurement in August 2024 ($2.9 \text{ ng/mL}$) and the most recent measurement in January 2025 ($4.8 \text{ ng/mL}$).
previous_notes
The previous notes confirm that the prior biopsy status was "None" as of the consultation date.

WHAT I DID NOT OPEN
I did not open the laboratory results because the moderator did not specifically ask for them in the plan, and the key findings regarding PSA density were already noted in the panel.

WHAT THIS SUPPORTS
FOR sampling this patient now
mpMRI report states a PI-RADS 4 lesion, which aligns with the EAU guideline trigger of $\ge 3$.
PSA trend shows a PSA velocity of $0.35 \text{ ng/mL/yr}$, which is a factor in risk stratification mentioned by the EAU guideline.
previous_notes confirm the prior biopsy status was "None," which is a factor in the guideline.
AGAINST sampling this patient now
nothing

WHERE THIS LEANS
The findings from the MRI report and the PSA trend align with the EAU guideline's trigger for biopsy, supporting the consideration of biopsy.
LEAN: biopsy

## Intervención 8 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The registrar successfully answered Q1 and Q2 by retrieving the `radiology_report` and `psa_trend`, which provided the necessary context for the decision.

ALIGNMENT WITH THE CLASSIFIER
The retrieved evidence aligns with the EXPERT-CLASSIFIER's suggestion of BIOPSY, as the MRI report confirmed a PI-RADS 4 lesion, and the PSA trend provided a velocity factor relevant to risk stratification.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What does the mpMRI prose state regarding the lesion size and extraprostatic extension? Answered by the registrar via the `radiology_report`: the lesion spans approximately 12 x 9 x 8 mm and shows early, focal enhancement.
Q2. What does the PSA trend reveal about the risk stratification? Answered by the registrar via the `psa_trend`: it reveals a PSA velocity of $0.35 \text{ ng/mL/yr}$ between August 2024 and January 2025.

WHAT CARRIES WEIGHT, AND WHY
The relevant variables are the PI-RADS score (4), which directly triggers the EAU guideline for biopsy, the PSA velocity ($0.35 \text{ ng/mL/yr}$), which is a factor in risk stratification, and the prior biopsy status ("None"), which is a factor in the guideline. The guideline does not support any variable that argues against biopsy in this context.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with a biopsy, as the retrieved evidence directly supports the EAU guideline trigger for biopsy based on the PI-RADS score and the relevant PSA trend.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 9 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

The decision to proceed with biopsy is supported by the PI-RADS score of 4, which aligns with the EAU guideline trigger. This is further supported by the PSA velocity of 0.35 ng/mL/yr and the prior biopsy status of 'None'. The retrieved MRI report confirmed a PI-RADS 4 lesion, and the cohort criterion strongly supports sampling in this scenario.

What carried weight: bx=noted, age=important, psa=important, vol=noted, psad=important, pirads=decisive
Documents this conference opened: radiology_report, psa_trend, previous_notes
